FI871087A - Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat Download PDF

Info

Publication number
FI871087A
FI871087A FI871087A FI871087A FI871087A FI 871087 A FI871087 A FI 871087A FI 871087 A FI871087 A FI 871087A FI 871087 A FI871087 A FI 871087A FI 871087 A FI871087 A FI 871087A
Authority
FI
Finland
Prior art keywords
thioxo
carbamoyl
tetrahydro
oxo
preparation
Prior art date
Application number
FI871087A
Other languages
English (en)
Finnish (fi)
Other versions
FI96683C (sv
FI871087A0 (sv
FI96683B (sv
Inventor
Karnail Singh Atwal
George Charles Rovnyak
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/008,037 external-priority patent/US4855301A/en
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI871087A0 publication Critical patent/FI871087A0/sv
Publication of FI871087A publication Critical patent/FI871087A/sv
Application granted granted Critical
Publication of FI96683B publication Critical patent/FI96683B/sv
Publication of FI96683C publication Critical patent/FI96683C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI871087A 1986-03-14 1987-03-12 Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat FI96683C (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83976786A 1986-03-14 1986-03-14
US83976786 1986-03-14
US91734986A 1986-10-09 1986-10-09
US91734986 1986-10-09
US07/008,037 US4855301A (en) 1986-10-09 1987-02-09 1,2,3,4-Tetrahydro-6-substituted-4-aryl(or heterocyclo)-3-((substituted amino)carbonyl)-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters
US803787 1987-02-09

Publications (4)

Publication Number Publication Date
FI871087A0 FI871087A0 (sv) 1987-03-12
FI871087A true FI871087A (sv) 1987-09-15
FI96683B FI96683B (sv) 1996-04-30
FI96683C FI96683C (sv) 1996-08-12

Family

ID=27358497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871087A FI96683C (sv) 1986-03-14 1987-03-12 Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat

Country Status (17)

Country Link
EP (1) EP0237347B1 (sv)
JP (1) JPH0819113B2 (sv)
KR (1) KR900005014B1 (sv)
CA (1) CA1337655C (sv)
DE (1) DE3770661D1 (sv)
DK (1) DK169031B1 (sv)
ES (1) ES2039234T3 (sv)
FI (1) FI96683C (sv)
GR (1) GR3002715T3 (sv)
HU (1) HU206091B (sv)
IE (1) IE60114B1 (sv)
IL (1) IL81800A0 (sv)
NO (1) NO871044L (sv)
PH (1) PH27052A (sv)
PL (1) PL153727B1 (sv)
PT (1) PT84479B (sv)
SU (1) SU1713437A3 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62267272A (ja) * 1986-05-15 1987-11-19 Sanwa Kagaku Kenkyusho Co Ltd 新規なジヒドロピリミジン化合物及びその塩、これらの製法並びに該化合物を有効成分とする循環器系作用剤
US4847379A (en) * 1987-11-30 1989-07-11 E. R. Squibb & Sons, Inc. 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
WO1996014846A1 (en) 1994-11-16 1996-05-23 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
AU714287B2 (en) * 1995-11-16 1999-12-23 Merck & Co., Inc. Dihydropyrimidines and uses thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
JP2002514199A (ja) * 1997-02-04 2002-05-14 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙ拮抗剤としてのジヒドロピリミドン誘導体
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU2003270562B2 (en) * 2002-09-12 2010-09-16 Diakron Pharmaceuticals, Inc. Calcium channel blockers
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214778A (ja) * 1984-03-08 1985-10-28 Suntory Ltd Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途
HUT42077A (en) * 1985-06-03 1987-06-29 Squibb & Sons Inc Process for producing diesters of 2-tioxo- or 2-oxo-pyrimidine-1,5-dicarboxylic acid and 1-acyl-pyrimidine-5-carboxylic acids and esters
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
NZ219299A (en) * 1986-03-14 1989-01-06 Squibb & Sons Inc Pyrimidine derivatives

Also Published As

Publication number Publication date
PH27052A (en) 1993-02-01
DK131887A (da) 1987-09-15
DK131887D0 (da) 1987-03-13
PT84479A (en) 1987-04-01
JPH0819113B2 (ja) 1996-02-28
NO871044D0 (no) 1987-03-13
EP0237347B1 (en) 1991-06-12
EP0237347A2 (en) 1987-09-16
GR3002715T3 (en) 1993-01-25
FI96683C (sv) 1996-08-12
FI871087A0 (sv) 1987-03-12
IE60114B1 (en) 1994-06-01
ES2039234T3 (es) 1993-09-16
HU206091B (en) 1992-08-28
DE3770661D1 (de) 1991-07-18
PT84479B (pt) 1990-08-31
EP0237347A3 (en) 1988-11-02
IE870633L (en) 1987-09-14
PL264629A1 (en) 1988-07-21
CA1337655C (en) 1995-11-28
PL153727B1 (en) 1991-05-31
IL81800A0 (en) 1987-10-20
HUT43832A (en) 1987-12-28
DK169031B1 (da) 1994-08-01
SU1713437A3 (ru) 1992-02-15
JPS62265271A (ja) 1987-11-18
KR870008856A (ko) 1987-10-21
KR900005014B1 (ko) 1990-07-16
FI96683B (sv) 1996-04-30
NO871044L (no) 1987-09-15

Similar Documents

Publication Publication Date Title
FI91152B (sv) Förfarande för framställning av terapeutiskt aktiva bensimidazolderivat
FI96861C (sv) Förfarande för framställning av terapeutiskt aktiva substituerade indolylpyrrolderivat
FI890282A0 (sv) Förfarande för framställning av terapeutiskt användbara 23,24-didehydro-25-hydroxikalciferolderivat
PT87754A (pt) Process for the preparation of new amino acid derivatives
FI94340C (sv) Förfarande för framställning av farmakologiskt verkande 1,5-diaryl-3-(w-substituerad-lägrealkyl)-pyrazoler
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
NO863061D0 (no) Fremgangsmaate for fremstilling av fysiologisk aktive fenoksyeddiksyrederivater.
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
NO871295D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
FI871087A (sv) Förfarande för framställning av terapeutiskt användbara 1,2,3,4-tetrahydro-3-karbamoyl-2-tioxo/oxo-5-pyrimidinkarboxylsyraderivat
FI96601C (sv) Förfarande för framställning av terapeutiskt aktiva tetrazolderivat
PT87153A (pt) Process for the preparation of acid ribofuranuronic derivatives
NO176273C (no) Analogifremgangsmåte for fremstilling av aktive substituerte benzamider
FI93444B (sv) Förfarande för framställning av terapeutiskt aktiva dihydropyridinföreningar
FI880467A0 (sv) Förfarande för framställning av terapeutiskt användbara substituerade 3,4-dihydro-2H-benzopyraner
NO870049D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
FI873350A (sv) Förfarande för framställning av terapeutiskt användbara 1,4-dihydropyridinderivat
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
FI900145A0 (sv) Förfarande för framställning av farmaceutiskt användbara 1,1-dioxo-cefem-4-karbotiolsyraderivat
FI93216C (sv) Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat
NO164243C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive 16,17-acetalsubstituerte pregnan-21-oinsyrederivater
FI893121A (sv) Förfarande för framställning av terapeutiskt aktiva 6,21-dimetyl-19-norprogestronderivat
NO171499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklo-penta(b)tiofen-6-karboksylsyre-derivater
NO166322C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nitroapovincaminsyrederivater.
FI89595B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2-(tioalkylamino)etyl-1H-imidazolderivat

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed
MM Patent lapsed

Owner name: E.R. SQUIBB & SONS, INC.